The starting price of the new Mustang, loaded with improvements, will be $24,425 including delivery charges, an increase of $1,090 over the current $23,335 for the cheapest current version.
When the new Mustang goes on sale in the fall, the lowest priced model will come with a 3.7-liter V-6 producing more than 300 horsepower. Two other engine options will also be available.
2015 MUSTANG: Radically new, retro, too
Even though the new pony car will be more expensive, Ford spokesman Brian Cotter points out it is loaded with standard features that aren't on the current Mustang. They include items like independent rear suspension, standard backup camera, steering wheel tilt and telescope and better interior materials throughout.
10 Best Heal Care Stocks To Own Right Now: ONYX Pharmaceuticals Inc.(ONXX)
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., develops and markets Nexavar (sorafenib) tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of kidney, liver, lung, thyroid, breast, and non-small cell lung cancers; clinical trials on carfilzomib, a proteasome inhibitor for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors; and Phase Ib/II clinical trial on Oprozomib, an oral proteasome inhibitor. In addition, Onyx Pharmaceuticals, Inc. is developing ONX 0914, an immunoproteasome inhibitor, which is in preclinical stage for the treatment of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, and lupus. Further, the company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., is conducting clinical trials on Regorafenib, a multi-kinase inhibitor to treat metastatic colorectal cancer and gastrointestinal stromal tumors. It has a collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore control of or intervene in the misregulated cell cycle in tumor cells. The company also has development and license agreements with BTG International Limited for the development and commercialization of ONX 0801, a novel targeted oncology compound; and Ono Pharmaceutical Co., Ltd. to develop and commercialize carfilzomib and Oprozomib for oncology indications in Japan. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in South San Francisco, California.
Advisors' Opinion:- [By Sean Williams]
Established pipeline suggestions
Celgene (NASDAQ: CELG ) : Celgene has been an absolute beast of a stock in 2013, and it could be just getting started if the company is able to meet on its guidance issued in January during the JPMorgan Healthcare Conference. At that annual meeting, Celgene noted its intentions to double its revenue, and triple EPS, by 2017 -- all through organic growth and drug approvals. Celgene has its blockbuster anemia drug Revlimid locked under patent protection for much of the remainder of this decade while its cancer drug Abraxane keeps racking up new indications. Already approved to treat metastatic breast cancer, and a first-line treatment for non-small cell lung cancer, Abraxane could also be well on its way to gaining approval in treating pancreatic cancer after improving PFS to 8.5 months from 6.7 months for the placebo in trials. Onyx Pharmaceuticals (NASDAQ: ONXX ) : Onyx shareholders also have plenty of reason to be dancing in the street over the past year, as its multiple myeloma cancer drug Kyprolis was approved in July, and its leading cancer treatment Nexavar, like Abraxane, continues to pile on the indications and positive data. Nexavar, which is co-developed with Bayer, is already approved by the FDA to treat renal cell carcinoma and unresectable hepatocellular carcinoma, but has shown promise in mid-stage trials in treating breast cancer, when combined with Roche's Xeloda and delivered promising results in a late-stage thyroid cancer trial. Roche: Finally, I'm not sure how any cancer discussion can be had where Roche isn't a possibility. I don't believe a single company appeared in more weekly Tackling Cancer
If taking big risks just isn't on your docket over the next couple of years, then the good news is that there are plenty of safer and/or less volatile selections to choose from that already have established pipelines. Here are three additional companies I would suggest you consider.
Top 10 Cheapest Companies To Own For 2014: Ishares Trust Dow Jones United States Financial (IYG)
iShares Dow Jones U.S. Financial Services Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Financial Services Index (the Index). The Index measures the performance of the financial services sector of the United States equity market and is a subset of the Dow Jones U.S. Financials Index. The Index includes companies in sectors, such as banks and investment management/brokers.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Mary Anne & Pamela Aden]
So, for now, the US stock market is the best overall market. So continue holding the stocks you have, which are mostly doing very well. If you want to buy new positions and increase your stock allocation, the following ETFs are among the strongest ETFs, and we recommend them for purchase: SPDR KBW Bank (KBE)
Consumer Discretionary SPDR (XLY)
Merrill Lynch Retail HOLDRS (RTH)
iShares Dow Jones US Financial Service (IYG)
PowerShares Dynamic Leisure & Entertainment (PEJ)
Subscribe to The Aden Forecast here��/P>
Top 10 Cheapest Companies To Own For 2014: Audiovox Corporation(VOXX)
VOXX International Corporation provides automotive and consumer electronic products, and accessories in the United States and internationally. The company?s products include mobile multimedia systems; auto sound systems comprising satellite radio, vehicle security, and remote start systems; portable DVD players; and personal and vehicle tracking devices. It also offers consumer electronics products, such as personal sound amplifiers, MP3 players, digital camcorders, docking stations, digital voice recorders, clock radios, digital picture frames, and home stereos; consumer electronics accessories comprising digital antennas, remote controls, wireless solutions, headphones, HDMI cables, power solutions, and media cleaning and care; and car audio and video products. In addition, the company provides audio products consisting of home theater systems; indoor and outdoor speaker lines; surround sound systems; sub woofers; professional installation products, such as cinema speake rs; and personal audio products, which include iPod docking stations and computer speakers. It markets its products under the Klipsch, RCA, Invision, Jensen, Audiovox, Terk, Acoustic Research, Advent, Code Alarm, CarLink, Omega, Excalibur, Prestige, SURFACE, Jamo, Energy, Mirage, Mac Audio, Magnat, Heco, Schwaiger, Oehlbach, and Incaar brands through a network of power retailers, mass merchandisers, hardware and independent retailers, 12-volt specialists, military exchanges, and automotive manufacturers, as well as through Internet. The company was formerly known as Audiovox Corporation and changed its name to VOXX International Corporation in December, 2011. VOXX International Corporation was founded in 1965 and is headquartered in Hauppauge, New York.
Advisors' Opinion:- [By Monica Gerson]
VOXX International (NASDAQ: VOXX) is projected to post its Q2 earnings at $0.09 per share on revenue of $186.73 million.
RPM International (NYSE: RPM) is expected to report its Q1 earnings at $0.71 per share on revenue of $1.13 billion.
- [By Seth Jayson]
VOXX International (Nasdaq: VOXX ) reported earnings on May 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Feb. 28 (Q4), VOXX International beat slightly on revenues and beat expectations on earnings per share.
Top 10 Cheapest Companies To Own For 2014: China Ming Yang Wind Power Group Ltd (MY)
China Ming Yang Wind Power Group Limited incorporated on February 26, 2009, is a wind turbine manufacturer in China, focusing on designing, manufacturing, selling and servicing megawatt-class wind turbines. The Company�� products consist of basic models of wind turbines, each with a rated power capacity of 1.5 megawatt (MW); wind turbines with a rated power capacity of 2.0MW, and 2.5/3.0MW SCD wind turbines. Each product type may be installed with one of three rotor blade models depending on the location and wind conditions. As of December 31, 2012, the Company had entered into sales contracts with 37 end customers to deliver 3,730 units of its wind turbines.
It cooperates with aerodyn Energiesysteme to develop its 1.5 megawatt wind turbines and share intellectual property rights. It also has obtained licenses from aerodyn Asia Co., Ltd. (aerodyn Asia) to manufacture and distribute wind turbines utilizing its super-compact drive (SCD) technology, with a rated power capacity of 6.0MW.
The Company�� customers are the Chinese state-owned power producers which include Huaneng, China Datang, Huadian, China Guodian Corporation, and China Power Investment Corporation (CPIC) or their alternative energy subsidiaries, such as China Longyuan Power Group Corporation Limited (Longyuan), a subsidiary of Guodian, and China Datang Corporation Renewable Power Co., Limited (Datang Renewable), a subsidiary of China Datang. It also sells wind turbines to regional alternative energy investment companies, regional power producers and wind farm operators in the private sector. Its facilities are located in Zhongshan, Tianjin, Jilin, Rudong, Dali and Inner Mongolia in China.
The Company produces megawatt-class, grid-connected, horizontal-axis wind turbines, equipped with a double-fed constant frequency induction generator, which is a design of the generator that enables the generator to produce electric current of a constant frequency as the shaft rotates at varying speeds causing! the generator rotor to rotate at varying speed. It offers 1.5 megawatt turbines specially designed and developed for the wind and weather conditions and power grids in China. Its 1.5 megawatt wind turbines are equipped with rotor blades with a post-installation diameter of 77.1 meters, 82.6 meters or 89.0 meters.
The Company has license rights under a license agreement from aerodyn Asia to manufacture and distribute 2.5/3.0MW SCD wind turbines and 6.0MW SCD wind turbines in China. The Company is focused on developing 3.8MW wind turbine model for larger multi-megawatt wind turbines.
The Company competes with Sinovel, Goldwind, Dongfang Electric, United Power, Vestas, Gamesa Corporacion Tecnologica S.A. and GE Energy.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 stock that looks ready to trigger a big breakout trade is China Ming Yang Wind Power Group (MY), a wind turbine manufacturer in China. This stock has been very hot over the last six months, with shares up sharply by 52%.
If you take a look at the chart for China Ming Yang Wind Power Group, you'll notice that this stock has been uptrending over the last few weeks, with shares moving higher from its low of $1.91 to its intraday high of $2.59 a share. During that uptrend, shares of MY have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of MY within range of triggering a big breakout trade.
Market players should now look for long-biased trades in MY if it manages to break out above some past overhead resistance levels at $2.58 to $2.80 a share high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.56 million shares. If that breakout hits soon, then MY will set up to re-test or possibly take out its next major overhead resistance levels at $3.35 to its 52-week high at $3.52 a share. Any high-volume move above those levels will then give MY a chance to tag $4 a share.
Traders can look to buy MY off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $2.30 a share, or near more support at $2.02 a share. One can also buy MY off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By John Udovich]
Small cap wind stock Broadwind Energy Inc (NASDAQ: BWEN) is up 203.7% since the start of the year, but investors might want to contain their excitement when they look closer at the�stock and�consider its�long term performance along with the performance of other wind investments like First Trust Global Wind Energy ETF (NYSEARCA: FAN) and wind energy stocks Vestas Wind Systems (OTCMKTS: VWDRY) and China Ming Yang Wind Power Group Ltd (NYSE: MY) to see whether BWEN is just blowing more hot air.
- [By Garrett Cook]
In trading on Tuesday, industrials shares were relative leaders, up on the day by about 0.26 percent. Top gainers in the sector included Perceptron (NASDAQ: PRCP), up 10.9 percent, China Ming Yang Wind Power Group (NYSE: MY), up 4.8 percent.
Top 10 Cheapest Companies To Own For 2014: Basilea Pharmaceutica AG (BSLN)
Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company�� anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company�� subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd. Advisors' Opinion:- [By Corinne Gretler]
Basilea Pharmaceutica AG (BSLN) increased 2.1 percent to 107.10 francs. The Swiss drug developer said the U.S. Food and Drug Administration granted orphan-drug designation to its isavuconazole for the treatment of zygomycosis, a life-threatening fungal infection.
Top 10 Cheapest Companies To Own For 2014: Amdocs Limited (DOX)
Amdocs Limited, together with its subsidiaries, provides software and services for communications, media, and entertainment industry service providers worldwide. It offers revenue management products, including convergent charging and billing, mediation, partner management, service delivery, compact convergence, and machine-to-machine solutions that manage the end-to-end network services revenue stream from offer definition to cash-in-hand and spans the consumer, business, and partner domains. The company also provides customer management products comprising multichannel selling, multichannel care, and proactive insight products that enable service providers to simplify the customer experience in all interaction channels and touch points; operations support systems, such as network planning, service fulfillment, service assurance, inventory and discovery, business service capture, network navigator, and radio parameter manager for fixed line, wireless, and cable networks; and network control products consisting of service controllers, home subscriber servers, policy controllers, data and Wi-Fi experience solutions, and intelligent diameter routing agents. In addition, it offers digital services, which include connected home solutions, mobile payments, digital commerce solutions, personalization, and unified communications and foundation. Further, the company provides advertising and media solutions that comprise sales experience, business agility, small-medium business experience, and business content and advertising syndication solutions. Additionally, it offers business consulting, system integration, information technology outsourcing and value process operation managed services, managed transformation, and product support services. Amdocs Limited was founded in 1988 and is based in St. Peter Port, Channel Islands.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Iron Mountain have fallen 2.3% to $25.72 today, while comparable have been mixed. Leidos Holdings (LDOS) has ticked up 0.6% to $46.28 and Amdocs (DOX) has risen 0.8% to $37.20. Maximus (MMS), on the other hand, has fallen 1.2% to $46.22 and Xerox (XRX) is off 0.3% to $10.62.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Amdocs (NYSE: DOX ) , whose recent revenue and earnings are plotted below.
Top 10 Cheapest Companies To Own For 2014: OraSure Technologies Inc.(OSUR)
OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States and internationally. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The company offers OraQuick ADVANCE HIV-1/2, a point-of-care qualitative test for antibodies to the human immunodeficiency virus type 1 and type 2; OraQuick HCV, a point-of-care qualitative test for antibodies to the hepatitis C virus; OraSure QuickFlu Rapid Flu A&B Test, a point-of-care qualitative test for antibodies to influenza Types A and B, including H1N1 infections; OraSure, an oral fluid collection device for the detection of antibodies to HIV-1 in an oral fluid sample in a laboratory setting; and Intercept, an oral fluid collection device for oral fluid drugs of abuse testing in a laboratory setting. In addition, it provides MICRO-PLATE DOA Assays that are used to detect the drugs in an oral fluid sample collected with intercept device; cryosurgical freezing systems for the removal of warts and other benign skin lesions; and cryosurgical systems for the removal of common and plantar warts. Further, OraSure Technologies sells immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test results obtained from the use of OraSure collection device; and Q.E.D., a point-of-care saliva alcohol test. The company sells its products through direct sales, strategic collaborations, and distributors to clinical laboratories, hospitals, clinics, community-based and other public health organizations, distributors, government agencies, physicians? offices, and commercial and industrial entities. It has collaboration agreement with Merck & Co. Inc. OraSure Technologies, Inc. was founded in 1979 and is based in Beth lehem, Pennsylvania.
Advisors' Opinion:- [By Seth Jayson]
OraSure Technologies (Nasdaq: OSUR ) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), OraSure Technologies beat slightly on revenues and met expectations on earnings per share. - [By Keith Speights]
Progress has also been made on the diagnostic front. The FDA approved OraSure Technologies' (NASDAQ: OSUR ) OraQuick home HIV test in July 2012. OraQuick allows an individual to use a mouth swab and find out the results within 40 minutes. The test hasn't exactly leaped off store shelves as of yet, though. OraSure reported only $1.5 million in gross sales for the OraQuick home test during the most recent quarter.
No comments:
Post a Comment